Lianhuan Pharmaceutical has been imposed a penalty of RMB 61.0382 million by the Tianjin Market Supervision and Management Committee for colluding with competitors to fix the price of dexamethasone sodium phosphate API. This fine constitutes 72.53% of the company's net profit from the previous year and is anticipated to impact its net profit for the year 2025.